Open an account

Pulmonx

LUNG · NASDAQ

$1.82+$0.07 (+4.00%)TodayMarket closed ·
Prev close $1.75

About LUNG

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 296 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

Employees
296
Headquarters
Redwood City, California
Listed
Oct 1, 2020
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
pulmonx.com

LUNG key statistics

Market cap
78.17M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
263.85K
Volume
525.80K
Open price
$1.75
High today
$1.86
Low today
$1.75
52 Week high
$2.89
52 Week low
$1.13

Pulmonx (LUNG) at a glance

As of Oct 20, 2026, Pulmonx (LUNG) shares are priced at $1.82, giving the company a market cap of 78.17M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.75 and $1.86. The current price is 4.0% above the day's low and 1.9% below its high.

Volume so far is 525.80K shares, above the average of 263.85K shares a day.

Over the past year Pulmonx has ranged from $1.13 to $2.89, and now sits 39% of the way up that range.

Pulmonx met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.24 per share against an estimate of -$0.2856.

The average analyst price target is $3.47, 90.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $3.47
Low
$2.53
Now
$1.82
High
$5.25

LUNG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 16.2% on average.

  1. Q3 FY24: reported -$0.36 per share against an estimate of -$0.4575
  2. Q4 FY24: reported -$0.33 per share against an estimate of -$0.4565
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.3802
  4. Q2 FY25: reported -$0.38 per share against an estimate of -$0.3808
  5. Q3 FY25: reported -$0.34 per share against an estimate of -$0.4267
  6. Q4 FY25: reported -$0.25 per share against an estimate of -$0.3998
  7. Q1 FY26: reported -$0.33 per share against an estimate of -$0.3332
  8. Q2 FY26: reported -$0.24 per share against an estimate of -$0.2856

LUNG news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Earnings Preview For Pulmonx

  • Pulmonx's Earnings: A Preview

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday

  • Press releaseBusiness Wire

    Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone

Similar companies

Companies in the same industry as Pulmonx

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.